You are here: Published Weight Loss Studies > Drug Treatment Studies > Phentermine
|
Index of published clinical studies related to Phentermine (Adipex-P, Fastin, Ionamin, Oby-Trim)
|
Research articles of clinical studies are listed by publication date, starting with the latest. Click on the title to view the abstract.
Well-designed clinical studies related to Phentermine (Adipex-P, Fastin, Ionamin, Oby-Trim)
Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. [2006 Oct 31]
Weight loss is correlated with an improved lipoprotein profile in obese postmenopausal women. [2000 Apr]
Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. [1999 Dec]
Pharmacologic induction of weight loss to treat type 2 diabetes. [1999 Jun]
An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. [1998 Sep 10]
Lifestyle modification in the pharmacologic treatment of obesity: a pilot investigation of a potential primary care approach. [1997 May]
Other clinical studies related to Phentermine (Adipex-P, Fastin, Ionamin, Oby-Trim)
Medical management of obesity. [2006 Sep-Oct]
Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status. [2006 Dec 05]
Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. [2006 Jun]
Weight loss medications--where do they fit in? [2006 Aug]
An update on the pharmacological treatment of obesity. [2006 Aug]
Central nervous system biogenic amine targets for control of appetite and energy expenditure. [2006 Feb]
Safety of drug therapies used for weight loss and treatment of obesity. [2006]
Safety of obesity drugs. [2005 Nov]
Pharmacotherapy for obesity. [2005]
Effects of oleoyl-estrone with dexfenfluramine, sibutramine or phentermine on overweight rats. [2005 Apr 25]
Pharmacological therapies for obesity. [2005 Mar]
Meta-analysis: pharmacologic treatment of obesity. [2005 Apr 05]
Primary pulmonary arterial hypertension presenting as diffuse micronodules on CT. [2004]
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. [2005 Jan 25]
The long-term management of obesity with continuing pharmacotherapy. [2004 Nov]
Pharmacotherapy of obesity: currently marketed and upcoming agents. [2002]
National trends in antiobesity medication use. [2003 May 12]
Anorexigen-induced cardiac valvulopathy and female gender. [2003 Apr]
Treatment of obesity: an update on anti-obesity medications. [2003 Feb]
Pharmacological management of obesity. [2002 Dec]
Herbal therapy for management of obesity: observations from a clinical endocrinology practice. [2001 Nov-Dec]
Drug treatment of obesity. [2001 Oct]
Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. [2001 Oct 24-31]
The relationship between health-related quality of life and weight loss. [2001 Sep]
Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. [2001 Aug 13-27]
Pharmacologic options for the treatment of obesity. [2001 Jul 15]
Appetite suppressants and valvular heart disease. [2001 Apr]
Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. [2000 Oct]
Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. [2000 Apr 05]
Novel anti-obesity drugs. [2000 Jun]
A concise review on the therapeutics of obesity. [2000 Oct]
[Obesity: principles of drug therapy] [2000 Aug]
[The obesity epidemics--do diet pills have a place in the treatment?] [2000 Jun 30]
Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy. [2000 Nov]
Drug treatment of obesity. [1999 Apr]
[Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants] [1998 Dec 01]
The effects of drugs used to treat obesity on the autonomic nervous system. [2000 May]
Appetite suppressants and cardiac valvulopathy. Current clinical perspectives. [1999 Oct]
Effects of phentermine and fenfluramine on alcohol consumption and alcohol withdrawal seizures in rats. [2000 Jan]
Initial weight loss as a predictor of response to obesity drugs. [1999 Dec]
The use of pharmacologic agents in the treatment of the obese patient. [1999 Oct]
Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. [1999 Dec 01]
Pharmaceutical cost savings of treating obesity with weight loss medications. [1999 Nov]
Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters. [1999 Sep]
Synergistic interactions between fenfluramine and phentermine. [1999 Jul]
Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. [1999 Jul]
[Orlistat (Xenical)] [1999 Jun]
Current concepts in the pharmacological management of obesity. [1999 Jun]
Use of dexfenfluramine, fenfluramine and phentermine and the risk of stroke. [1999 May]
Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with significant weight loss. [1999 May]
Acute interstitial nephritis following treatment with anorectic agents phentermine and phendimetrazine. [1998 Oct]
A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. [1998 Sep 10]
The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. [1998 Sep 10]
The fen-phen finale: a study of weight loss and valvular heart disease. [1998 Jul]
Interaction of phentermine plus fenfluramine: neurochemical and neurotoxic effects. [1998 Apr]
A close look at fenfluramine and dexfenfluramine. [1998 Mar-Apr]
Obesity. [1998 Jan]
Long-term drug treatment of obesity in a private practice setting. [1997 Nov]
Pharmaceutical treatment of obesity. [1997 Dec]
Three cases of comprehensive dietary therapy and pharmacotherapy of patients with complex obesity-related diseases. [1997 Aug]
Pharmacological approaches to intervention. [1997 Mar]
Anesthetic considerations for the new antiobesity medications. [1996 Dec]
Combined drug treatment of obesity. [1995 Nov]
[Anorexigenic drugs in the treatment of obesity] [1995 May]
Long-term weight loss: the effect of pharmacologic agents. [1994 Nov]
Report on the NIH Workshop on Pharmacologic Treatment of Obesity. [1994 Aug]
Appetite suppressants. A review. [1992 Jun]
Long-term weight control study. VII (weeks 0 to 210). Serum lipid changes. [1992 May]
Long-term weight control study. VI. Individual participant response patterns. [1992 May]
Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication. [1992 May]
Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase. [1992 May]
Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. [1992 May]
Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. [1992 May]
Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. [1992 May]
Effect of weight loss on serum lipoprotein(a) concentrations in an obese population. [1991 Jul]
|
